This clinical trial is focused on patients who are critically ill and undergoing a treatment called continuous renal replacement therapy (CRRT). This therapy is often used for patients with severe kidney problems. The study is investigating the use of a medication combination called ceftazidime-avibactam. Ceftazidime is an antibiotic that fights bacteria, and avibactam helps ceftazidime work better by preventing bacteria from breaking it down.

The purpose of the study is to develop an optimized dosing regimen of ceftazidime-avibactam for these patients. Participants in the study will receive the medication intravenously, which means it will be given directly into a vein. The study will monitor how the medication is processed in the body and how well it reaches the desired levels to fight infections effectively. This will help in understanding the best way to dose the medication for patients who are receiving CRRT.

The study will take place over a period of time, and researchers will collect information on how the medication behaves in the body, known as pharmacokinetics. This information will be used to create a model that helps determine the best dosing strategy for ceftazidime-avibactam in critically ill patients. The ultimate goal is to ensure that patients receive the most effective treatment possible while minimizing any potential side effects.